with other rivals including Johnson & Johnson’s IL-12 and IL-23 inhibitor Stelara (ustekinumab) and Takeda Pharma’s α4β7 inhibitor Entyvio (vedolizumab), both of which are approved for both ...

Ebdarokimab is a novel humanized monoclonal antibody targeting IL-12/IL-23, developed by Akeso. Ebdarokimab is indicated for the treatment of psoriasis, ulcerative colitis, and other autoimmune ...

It will compete with other biologic therapies for Crohn's, including J&J's IL-12 and IL-23 inhibitor Stelara (ustekinumab), Takeda's Entyvio (vedolizumab) and Biogen's Tysabri (natalizumab ...

Sustained Long-Term Efficacy: Patients receiving ebdarokimab injection 135mg every 12 weeks (Q12W) for maintenance therapy achieved long-term durable efficacy, with a PASI 75 response rate of 77.9 ...

Ebdarokimab is a novel humanized monoclonal antibody targeting IL-12/IL-23, developed by Akeso. Ebdarokimab is indicated for the treatment of psoriasis, ulcerative colitis, and other autoimmune ...